Insights

Insights

Filter by:
Governing Laws
Sector
Sub-sector
Service Patents & innovation
Sub-service
Hot Topics
Synapse

COVID-19 postponement of MDR implementation date – how does this fit with Brexit?

26 May 2020
IN-DEPTH ANALYSIS

by Adrian Toutoungi

Click here to find out more
Brands & advertising

Ex parte injunctions in the Netherlands

18 May 2020
IN-DEPTH ANALYSIS

by Maarten Rijks

Click here to find out more
Coronavirus

COVID-19: Courts and IP offices in the Netherlands

12 May 2020
IN-DEPTH ANALYSIS

by Dr. Wim Maas and Maarten Rijks

Click here to find out more
Patents & innovation

Managing chaos – how will entrepreneurs cope with the upcoming crisis?

8 May 2020
QUICK READ

by multiple authors

Click here to find out more
Patents & innovation

German Federal Court of Justice Hearing on FRAND

7 May 2020

by Dr. Michael Schächinger

Click here to find out more
Patents & innovation

The deadlock on the unified patent convention

The decision of the Federal Constitutional Court (Case No 2 BvR 739/17) on the constitutionality of the UPC-Act of Approval

4 May 2020

by Dr. Anja Lunze, LL.M.

Click here to find out more
Coronavirus

EUIPO extends deadline again

30 April 2020
QUICK READ

by Louise Popple

Click here to find out more
Synapse

Patents diary: April 2020

30 April 2020
QUICK READ

by Dr Paul England

Click here to find out more
Life sciences & healthcare

Everything biologic and biosimilar in-house counsel need to know about COVID-19

29 April 2020

by multiple authors

Click here to find out more
Patents & innovation

Video conferencing in patent disputes

22 April 2020

by Dr. Nora E. Wessendorf, LL.M. (Washington)

Click here to find out more
Interface - The latest in life sciences

Patent pools: an easy licensing option for COVID-19 drugs and SARS CoV 2 vaccines?

An exploration of patent pools, R&D and current initiatives.

22 April 2020
IN-DEPTH ANALYSIS

by Dr. Anja Lunze, LL.M. and Dr. Jan Phillip Rektorschek

2 of 6 Insights

Click here to find out more
Patents & innovation

COVID-19 and public compulsory licensing of drugs in Europe

17 April 2020
IN-DEPTH ANALYSIS

by multiple authors

Click here to find out more